Florida-based Human Continuum Inc. has closed a USD 5.13 million seed financing round to advance its exosome-based therapeutics and diagnostics platform, positioning the early-stage company among a growing cohort of firms attracting longevity medicine funding through extracellular vesicle technology. The capital will support development of a multi-indication platform spanning orthopedics, dermatology, and systemic inflammation, with an initial focus on conditions such as osteoarthritis that affect tens of millions of adults globally.
The round was funded by existing shareholders, the company said, with no named institutional lead investors disclosed. Proceeds will be directed toward expanding Human Continuum's technical team and strengthening research and development capabilities across its pipeline. The company has not disclosed prior equity financing rounds, making this the first publicly announced capital raise for the firm. Earlier in 2026, the company appointed Dr. Michael Milligan, MD, MBA as Chief Medical Officer, adding clinical leadership with more than 25 years of sports medicine and musculoskeletal experience, including roles at Hospital for Special Surgery Florida and the Andrews Institute.
A multi-indication exosome platform
Human Continuum's platform is built around two distinct exosome source types: platelet-derived exosomes and plant-derived exosomes. The platelet-derived exosomes program seeks to isolate and standardize the regenerative signaling molecules released by platelets — without the platelets themselves — to deliver what the company describes as a cell-free, minimally invasive approach to modulating inflammation and supporting cellular repair. The lead program is being developed as an investigational intravenous infusion designed to evaluate effects on inflammatory biomarkers.
Exosomes are nanoscale extracellular vesicles that carry proteins, lipids, and nucleic acids between cells, functioning as natural mediators of intercellular communication. The therapeutic rationale for platelet-derived exosomes rests on evidence that platelets release bioactive signals that promote tissue regeneration and modulate immune responses — effects that a standardized, acellular preparation could theoretically deliver more consistently than platelet-rich plasma or whole-cell approaches.